- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00286624
Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation (NITA)
A One-Year, Single-Center, Prospective, Open-Label Study of the Safety, Tolerability, and Preliminary Efficacy of Anti-Thymocyte Globulin, Cyclosporine, and RAD in Type 1 Diabetic Islet Transplant Recipients
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a Phase I/II study designed to assess the safety and efficacy of sequential islet allotransplantation for the reestablishment of stable glycemic control in type 1 diabetic recipients. A total of 6 patients with type 1 diabetes have received up to three transplants of islets from different donor pancreases.
Potential candidates for islet allotransplantation included patients age 18 and older with type 1 diabetes. Induction immunotherapy for the first transplant consisted of anti-thymocyte globulin; basiliximab was used for any subsequent transplants. Peritransplant anti-inflammatory treatment with etanercept was given for each islet transplant. Maintenance immunosuppression is with cyclosporine and RAD. It is felt that those patients in whom metabolic lability/instability, reduced awareness of hypoglycemia, poor glycemic control, and progressive secondary complications persist despite continued and intensive efforts made in close cooperation with their diabetes care team are particularly likely to have a favorable benefit/risk ratio.
Adverse events, irrespective of their presumed relationship to the transplantation of allogeneic islets and/or protocol-regulated treatment products (concomitant therapy), are being monitored and recorded throughout the first year after the final islet transplant.
The proportion of single and sequential donor islet allograft recipients with full (insulin independence and HbA1c <7%) and partial (insulin dependence, basal or arginine-stimulated C-peptide levels of greater or equal to 0.5 ng/mL and HbA1c <7%) islet graft function at one year after the final islet transplant will be assessed. The impact of islet transplantation on quality of life will also be assessed.
The predictive value for posttransplant insulin independence of factors such as insulin resistance before and at intervals after pancreatectomy, cellular composition of the transplant, number of beta cells transplanted; and viability and insulin secretory response of isolated islets are being assessed.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Primary islet allotransplant
- Patients with type 1 diabetes mellitus under intensive insulin management
- Age 18 or older
- Ability to give written informed consent
Exclusion Criteria:
- Age less than 18 years.
- BMI >26 kg/m2.
- Insulin requirement of > 50 IU per day.
- Positive C-peptide response to intravenous arginine stimulation.
- Untreated proliferative retinopathy.
- Creatinine clearance < 60 ml/min/1.73 m2 for females and 70 ml/min/1.73 m2 for males.
- Serum creatinine >1.3 mg/dl for females, >1.5 mg/dl for males.
- Previous pancreas or islet transplant.
- Presence of history of panel-reactive anti-HLA antibodies >10%.
- Positive pregnancy test, or presently breast-feeding, or failure to follow effective contraceptive measures.
- Active infection including hepatitis C, hepatitis B, HIV, or TB (or under treatment for suspected TB).
- Negative screen for Epstein-Barr Virus (EBV).
- Invasive aspergillus infection within year prior to study entry.
- History of malignancy.
- Active alcohol or substance abuse
- History of non-adherence to prescribed regimens.
- Psychiatric disorder making the subject not a suitable candidate for transplantation.
- Inability to provide informed consent.
- Baseline Hgb < 11.7 g/dl in females, or < 13 g/dl in males; lymphopenia (<1,000/microL), or leukopenia (<3,000 total leukocytes/microL), or an absolute CD4+ count <500/microL., or platelets <150,000/microL
- History of coagulopathy or medical condition requiring long-term anticoagulant therapy after transplantation or patient with INR >1.5.
- Severe co-existing cardiac disease.
- Baseline liver function tests outside of normal range or history of significant liver disease.
- Active peptic ulcer disease.
- Severe unremitting diarrhea or other gastrointestinal disorders potentially interfering with the ability to absorb oral medications.
- Presence of severe allergy requiring acute or chronic treatment, or hypersensitivity to drugs similar to RAD (e.g., macrolides).
- Known hypersensitivity to rabbit proteins.
- Hyperlipidemia (fasting LDL cholesterol > 130 mg/dl, treated or untreated; and/or fasting triglycerides > 200 mg/dl).
- Addison's disease.
- Under treatment requiring chronic use of systemic steroids.
- Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 1
Allogeneic islet transplantation with anti-thymocyte globulin induction and cyclosporine and RAD maintenance immunosuppression
|
Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans.
First infusion to contain at least 5,000 islet equivalents/kg body weight.
Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
Otros nombres:
Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID.
The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
Otros nombres:
A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2.
The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
Otros nombres:
Cyclosporine started on day +1 relative to the first islet transplant.
Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
• The incidence, timing, and severity of adverse events during one year after the first and any subsequent islet transplants.
Periodo de tiempo: 1 year
|
1 year
|
|
• Incidence and severity of hypoglycemia during the first year after the first and any subsequent islet transplants.
Periodo de tiempo: 1 yr
|
1 yr
|
|
• The proportion of recipients who develop alloantibodies directed at islet donor alloantigens during the first year after the first and any subsequent islet transplants.
Periodo de tiempo: 1 year
|
1 year
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
• The proportion of subjects who achieve insulin independence in the first year after single-donor or sequential transplantation.
Periodo de tiempo: 1 year
|
1 year
|
|
• The proportion of islet allograft recipients with full and partial islet graft function at one year after the most recent islet transplant.
Periodo de tiempo: 1 year
|
1 year
|
|
• Glycemic control and insulin secretory responses during the first year after the first and any subsequent transplants.
Periodo de tiempo: 1 year
|
1 year
|
|
• The effect of donor age, pretransplant islet insulin secretory response in vitro, number of transplanted islet equivalents (IEQ), number of transplanted beta cells, pretransplant recipient insulin requirements and action, recipient body mass index (BM
Periodo de tiempo: Day of transplant
|
Day of transplant
|
|
• The impact of islet transplantation on the quality of life of transplant recipients.
Periodo de tiempo: 1 year
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Trastornos del metabolismo de la glucosa
- Enfermedades metabólicas
- Enfermedades del sistema inmunológico
- Enfermedades autoinmunes
- Enfermedades del sistema endocrino
- Diabetes mellitus
- Diabetes Mellitus, Tipo 1
- Hipoglucemia
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Inhibidores de enzimas
- Agentes antirreumáticos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes dermatológicos
- Agentes antifúngicos
- Inhibidores de calcineurina
- Everolimus
- Suero Antilinfocito
- Ciclosporina
- Ciclosporinas
Otros números de identificación del estudio
- 0207M29841
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .